Page 73 - Helicobacter pylori and Gastric Cancer: From Tumor microenvironment to Immunotherapy
P. 73

 Reference
1. den Hoed, C.M. and E.J. Kuipers, Gastric Cancer: How Can We Reduce the Incidence of this Disease? Curr Gastroenterol Rep, 2016. 18(7): p. 34.
2. Jemal, A., et al., Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 2010. 19(8): p. 1893-907.
3. Wagner, A.D., et al., Chemotherapy for advanced gastric cancer. Cochrane
Database Syst Rev, 2017. 8: p. CD004064.
4. Muro, K., et al., Pembrolizumab for patients with PD-L1-positive advanced
gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.
Lancet Oncol, 2016. 17(6): p. 717-726.
5. Kei, M., et al., Relationship between PD-L1 expression and clinical outcomes
in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. Journal of Clinical Oncology, 2015. 33(3_suppl): p. 3-3.
6. Muro, K., et al., Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. Journal of Clinical Oncology, 2015. 33(3_suppl): p. 3-3.
7. Hodi, F.S., et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010. 363(8): p. 711-23.
8. Robert, C., et al., Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med, 2015. 372(4): p. 320-30.
9. Schachter, J., et al., Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open- label phase 3 study (KEYNOTE-006). Lancet, 2017.
10. Reck, M., et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 2016. 375(19): p. 1823-1833.
11. Brahmer, J., et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 2015. 373(2): p. 123-35.
12. Borghaei, H., et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med, 2015. 373(17): p. 1627-39.
13. Motzer, R.J., et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med, 2015. 373(19): p. 1803-13.
                                 Immunotherapy Checkpoint Inhibition
Immuno checkpoint inhibition
67
71
3












































































   71   72   73   74   75